LIVE: NOV. 12, 2019
TIME: 11:00 AM EST (UTC -5)
Join Dr. Robert Gould and Michael Girand as they discuss methods and applications for the use of EEG as a biomarker for sleep, substance use disorder and CNS disorders.
Electroencephalography (EEG) represents one of the primary methods to measure brain function in a non-invasive manner in humans and animals, thus providing a highly translational and powerful research tool to enhance basic academic as well as drug discovery research programs.
In this webinar sponsored by Data Sciences International (DSI), Dr. Robert Gould, Assistant Professor of Physiology and Pharmacology at Wake Forest School of Medicine, will highlight several basic methods and applications for using EEG in freely moving rodents to enhance or complement research on CNS disorders. One well-known application of quantitative EEG (qEEG) is to examine different oscillatory patterns of brain function (e.g. diurnal rhythm, disease progression, pharmacological manipulations, etc.). In addition, Dr. Gould will discuss how EEG can be used to study sleep architecture and arousal, addiction/substance use disorder, schizophrenia and drug discovery.
Michael Girand, Scientific Applications Manager at DSI, will convey a holistic approach when studying CNS based applications and discuss how researchers can improve their study design and get more endpoints out of the animal model.
Key discussion topics include:
- Multiple translational applications of EEG to enhance your research
- Highlighting sleep disruptions across CNS disorders
- Understanding how to apply EEG to measure changes in brain function
- Tools available to create a robust study design
- The collaborative approach between technologies, scientists, and DSI
Assistant Professor, Physiology and Pharmacology
Wake Forest School of Medicine
Dr. Robert Gould conducts translational pharmacology research pairing complex behavioral tasks with measures of brain function to aid our understanding of CNS disorders and develop novel pharmacotherapies. He has extensive experience examining pharmacological manipulations on behavior/brain function across preclinical models of addiction, depression, anxiety, schizophrenia and aging.
Dr. Gould’s research currently involves investigating how altered brain function contributes to substance use disorder (SUD) and how normalizing aspects of aberrant brain function may facilitate successful addiction treatment. Modeling and attempting to reverse these substance-induced disorders, including sleep disturbances, represents a new treatment approach for SUD with direct application to human studies and clinical trials.
Scientific Applications Manager
Data Sciences International
Since joining DSI in 2007, Michael Girand’s responsibilities have included product management, technical and application support and sales. Managing the Scientific Applications team at DSI, he works with scientists to better understand the research environment and its challenges to take a collaborative approach to help scientists reach their research goals.
Prior to working with DSI, he was a Research Scientist and Study Director at Warner-Lambert/Parke-Davis and Pfizer in Ann Arbor, MI for 12 years. While there, he had the opportunity to work in a variety of departments including Cardiovascular Pharmacology, General Toxicology, and Safety Pharmacology.